178 related articles for article (PubMed ID: 12413931)
21. Serous borderline tumours of the ovary.
Kurman RJ; Seidman JD; Shih IM
Histopathology; 2005 Sep; 47(3):310-5. PubMed ID: 16115232
[TBL] [Abstract][Full Text] [Related]
22. Apoptotic and proliferative activity in ovarian benign, borderline and malignant tumors.
Liu A; Chen L; Ngan HY; Khoo US; Zhao Y; Cheung AN
Chin Med Sci J; 2002 Jun; 17(2):106-11. PubMed ID: 12906164
[TBL] [Abstract][Full Text] [Related]
23. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
Tan Y; Sinniah R; Bay BH; Singh G
J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
[TBL] [Abstract][Full Text] [Related]
24. Pathology of ovarian carcinoma.
Seidman JD; Kurman RJ
Hematol Oncol Clin North Am; 2003 Aug; 17(4):909-25, vii. PubMed ID: 12959182
[TBL] [Abstract][Full Text] [Related]
25. Mucinous borderline and malignant tumors of the ovary. A clinicopathologic and DNA ploidy study of 92 cases.
Guerrieri C; Högberg T; Wingren S; Fristedt S; Simonsen E; Boeryd B
Cancer; 1994 Oct; 74(8):2329-40. PubMed ID: 7922984
[TBL] [Abstract][Full Text] [Related]
26. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
[TBL] [Abstract][Full Text] [Related]
27. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours.
Fraggetta F; Pelosi G; Cafici A; Scollo P; Nuciforo P; Viale G
Virchows Arch; 2003 Dec; 443(6):782-6. PubMed ID: 14576939
[TBL] [Abstract][Full Text] [Related]
28. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
[TBL] [Abstract][Full Text] [Related]
29. Ovarian tumours: a study of 282 cases.
Pilli GS; Suneeta KP; Dhaded AV; Yenni VV
J Indian Med Assoc; 2002 Jul; 100(7):420, 423-4, 447. PubMed ID: 12674165
[TBL] [Abstract][Full Text] [Related]
30. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion.
Prat J; De Nictolis M
Am J Surg Pathol; 2002 Sep; 26(9):1111-28. PubMed ID: 12218568
[TBL] [Abstract][Full Text] [Related]
31. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'.
Lee KR; Scully RE
Am J Surg Pathol; 2000 Nov; 24(11):1447-64. PubMed ID: 11075847
[TBL] [Abstract][Full Text] [Related]
32. Surface epithelial tumours of the ovary.
Maheshwari V; Tyagi SP; Saxena K; Tyagi N; Sharma R; Aziz M; Hameed F
Indian J Pathol Microbiol; 1994 Jan; 37(1):75-85. PubMed ID: 8088904
[TBL] [Abstract][Full Text] [Related]
33. Mucinous tumors of the ovary: a review.
Hart WR
Int J Gynecol Pathol; 2005 Jan; 24(1):4-25. PubMed ID: 15626914
[TBL] [Abstract][Full Text] [Related]
34. Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer.
Ahmed N; Riley C; Rice GE; Quinn MA; Baker MS
J Histochem Cytochem; 2002 Oct; 50(10):1371-80. PubMed ID: 12364570
[TBL] [Abstract][Full Text] [Related]
35. Serous tumours of low malignant potential (serous borderline tumours): moving toward détente.
Longacre TA; Kempson RL; Hendrickson MR
Histopathology; 2005 Sep; 47(3):315-8. PubMed ID: 16115233
[No Abstract] [Full Text] [Related]
36. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
[TBL] [Abstract][Full Text] [Related]
37. Calcifications in mucinous and serous cystic ovarian tumors.
Okada S; Ohaki Y; Inoue K; Kawamura T; Hayashi T; Kato T; Kumazaki T
J Nippon Med Sch; 2005 Feb; 72(1):29-33. PubMed ID: 15834205
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis V; Pavlidis N; Agnantis NJ
Histol Histopathol; 2006 Apr; 21(4):341-7. PubMed ID: 16437378
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors.
McCluggage WG; Strand K; Abdulkadir A
Int J Gynecol Cancer; 2002; 12(1):62-5. PubMed ID: 11860537
[TBL] [Abstract][Full Text] [Related]
40. Cell polarity reversal in ovarian low-grade serous carcinomas and micropapillary serous borderline tumours: immunohistochemical observations.
Hui Y; Ou JJ; Sung CJ; Lawrence WD; Quddus MR
Histopathology; 2016 Nov; 69(5):892-894. PubMed ID: 27271798
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
